Key Highlights:
- Piramal Pharma has acquired an additional 40.67% stake in Yapan Bio for ₹76 crore ($7.95 million), taking its total ownership to 74% and converting the Hyderabad-based vaccines and biologics CDMO into a subsidiary. Piramal has held a stake in Yapan Bio since 2021.
- Yapan Bio specializes in process development, characterization, and Phase I and II GMP manufacturing for vaccines and biologics. Its integration into Piramal Pharma Solutions (PPS) will strengthen Piramal’s large-molecule capabilities and enable customers to access more complex, integrated biologics development and manufacturing services across the product lifecycle.
- Yapan Bio also supports PPS’s ADCelerate™ platform, which offers integrated Phase I ADC development from R&D to GMP manufacturing in as little as 12 months. The acquisition is expected to enhance the platform and strengthen Piramal’s ability to develop and scale complex biologics and ADCs while addressing growing global demand for advanced therapies.
Implications:
Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process development, characterization, and Phase I/II GMP manufacturing for vaccines and biologics and embedding these capabilities directly into Piramal Pharma Solutions (PPS). 1035 This strengthens PPS’s large‑molecule and ADC offering—Yapan already supports the ADCelerate platform that promises Phase I ADC development from R&D to GMP in ~12 months—so Piramal can better win integrated, end‑to‑end biologics/ADC programs and scale complex therapies as global demand for advanced modalities grows.
Source: PRnewswire
